Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Moser, Bernhard ^a   Janik, Stefan ^a   Schiefer, Ana Iris ^a   Müllauer, Leonhard ^a   Bekos, Christine ^a   Scharrer, Anke ^a   Mildner, Michael ^b   Rényi Vámos, Ferenc ^c   Klepetko, Walter ^a   Ankersmit, Hendrik Jan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CENTROBLAST; CENTROCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; FEMALE; FETUS; GERMINAL CENTER; HASSALL BODY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MIDDLE AGED; MYASTHENIA; PLASMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THYMOCYTE; THYMOMA; THYMUS; THYMUS CANCER; THYMUS HYPERPLASIA; BLOOD; GENE EXPRESSION; GENETICS; INFANT; METABOLISM; MYASTHENIA GRAVIS; NEOPLASM; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; FETUS; GENE EXPRESSION; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; RECEPTORS, IMMUNOLOGIC; THYMUS GLAND; THYMUS HYPERPLASIA; THYMUS NEOPLASMS; YOUNG ADULT;

EID: 84899103912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094118     Document Type: Article

References (73)

1. Duwe BV, Sterman DH, Musani AI. (2005) Tumors of the mediastinum. Chest 128(4): 2893-909. (Pubitemid 41507651)
2. Ströbel P, Marx A, Zettl A, Müller-Hermelink HK. (2005) Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 35(10): 805-11.
3. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. (2011) The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol 6(7 Suppl 3): S1710-6.
4. Moser B, Scharitzer M, Hacker S, Ankersmit J, Matilla JR, et al. (2012) Thymomas and Thymic Carcinomas: Prognostic Factors and Multimodal Management. Thorac Cardiovasc Surg DOI: 10.1055/s-0032-1322611
5. Engels EA. (2010) Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5(10 Suppl 4): S260-5.
6. Castleman B (1955) Atlas of tumor pathology. Tumors of the thymus gland, fascicle 19. Armed Forces Institute of Pathology, Washington, DC
7. Rosai J, Levine GD (1976) Atlas of tumor pathology. Tumors of the thymus, Second series, fascicle 13. Armed Forces Institute of Pathology, Washington, DC
8. Vincent A. (2002) Unravelling the pathogenesis of myasthenia gravis, Nat. Rev. Immunol 2(10): 797-804.
9. Moser B, Bekos C, Zimprich F, Nickl S, Klepetko W, et al. (2012) The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis. Biochem Biophys Res Commun 420(1): 96-101.
10. Cavalcante P, Le Panse R, Berrih-Aknin S, Maggi L, Antozzi C, et al. (2011) The thymus in myasthenia gravis: Site of "innate autoimmunity"? Muscle Nerve 44(4): 467-84.
11. Lara PN Jr. (2000) Malignant thymoma: current status and future directions. Cancer Treat Rev 26(2): 127-131
12. Johnson SB, Eng TY, Giaccone G, Thomas CR Jr. (2001) Thymoma: update for the new millennium. Oncologist 6(3): 239-46.
13. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 25;267(21): 14998-5004.
14. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, et al. (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface, J. Biol. Chem 267(21) 14987-14997.
15. Leclerc E, Sturchler E, Vetter SW. (2010) The S100B/RAGE axis in Alzheimer's disease. Cardiovasc. Psychiatry Neurol 539581. doi: 10.1155/2010/539581.
16. Halayko AJ, Ghavami S. (2009) S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can. J. Physiol. Pharmacol 87(10): 743-755 (Review).
17. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, et al. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases, Nature 405(6784): 354-360. (Pubitemid 30337069)
18. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, et al. (1996) The receptor for advanced glycation endproducts (RAGE) mediates the interaction of AGE-beta2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98: 1088-1094. (Pubitemid 26299919)
19. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, et al. (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9: 287-293. (Pubitemid 36362783)
20. Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, et al. (2005) RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 201: 473-484. (Pubitemid 40229421)
21. Moser B, Desai DD, Downie MP, Chen Y, Yan SF, et al. (2007) Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol 15;179(12): 8051-8
22. Moser B, Szabolcs MJ, Ankersmit HJ, Lu Y, Qu W, et al. (2007) Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant 7(2): 293-302 (Pubitemid 46096322)
23. Kalea AZ, Schmidt AM, Hudson BI. (2011) Alternative splicing of RAGE: roles in biology and disease, Front Biosci. 1(17): 2756-2770.
24. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. (2013) HMGB1 in Cancer: Good, Bad, or Both? Clin Cancer Res 1;19(15): 4046-57.
25. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-88. Review.
26. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, et al. (2009) RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 17;7: 17. Review.
27. Hiwatashi K, Ueno S, Abeyama K, Kubo F, Sakoda M, et al. (2008) A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol 15(3): 9 23-33.
28. Dougan M, Dranoff G. (2008) Inciting inflammation: the RAGE about tumor promotion. J Exp Med 205(2): 267-70. (Pubitemid 351281591)
29. Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, et al. (2011) Evidence That Serum Levels of the Soluble Receptor for Advanced Glycation End Products Are Inversely Associated with Pancreatic Cancer Risk: A Prospective Study. Cancer Res 71: 3582-3589.
30. Lin L, Zhong K, Sun Z, Wu G, Ding G. (2012) Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 138: 11-22.
31. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, et al. (2011) Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 20: 1430-1438.
32. Tafani M, Di Vito M, Frati A, Pellegrini L, De Santis E, et al. (2011) Proinflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. Journal of Neuroinflammation 8: 32.
33. Li R, Deng Y. (2010) [Expression of RECK, RAGE and MMP-9 in nasopharyngeal carcinoma and its significance]. [Article in Chinese] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 24(18): 823-7.
34. Zhu X, Jin L, Zou S, Shen Q, Jiang W, et al. (2013) Immunohistochemical Expression of RAGE and Its Ligand (S100A9) in Cervical Lesions. Cell Biochem Biophys 66(3): 843-50.
35. Xu XC, Gao H, Zhang WB, Abuduhadeer X, Wang YH. (2013) Clinical significance of immunogenic cell death biomarker rage and early growth response 1 in human primary gastric adenocarcinoma. Int J Immunopathol Pharmacol 26(2): 485-93.
36. Wang X, Cui E, Zeng H, Hua F, Wang B, et al. (2012) RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One 7(10): e43734.
37. Chen G, Marx A, Chen WH, Yong J, Puppe B, et al. (2002) New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 95(2): 420-429. (Pubitemid 34787609)
38. Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, et al. (2012) p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 15;72(8): 1996-2005.
39. Sasahira T, Akama Y, Fujii K, Kuniyasu H. (2005) Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446(4): 411-5. (Pubitemid 40674848)
40. Kuniyasu H, Chihara Y, Takahashi T. (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10(2): 445-8.
41. Roithmaier S, Haydon AM, Loi S, Esmore D, Griffiths A, et al. (2007) Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 26(8): 845-9. (Pubitemid 47214568)
42. Burnet M. (1957) Cancer; a biological approach. I. The processes of control. Br Med J 6;1(5022): 779-86.
43. Thomas L. (1982) On immunosurveillance in human cancer. Yale J Biol Med 55(3-4): 329-33.
44. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 25;356(9244): 1795-9.
45. Weksler B, Nason KS, Mackey D, Gallagher A, Pennathur A. (2012) Thymomas and extrathymic cancers. Ann Thorac Surg 93(3): 884-8.
46. Fujii Y. (2011) Published guidelines for management of thymoma. Thorac Surg Clin 21(1): 125-9.
47. Cosgrove D, Chan SH, Waltzinger C, Benoist C, Mathis D. (1992) The thymic compartment responsible for positive selection of CD4+ T cells. Int Immunol 4(6): 707-10.
48. Ma CY, Ma JL, Jiao YL, Li JF, Wang LC, et al. (2012) The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol 75(6): 614-22.
49. Urbonaviciute V, Voll RE. (2011) High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 270(4): 309-18
50. Pisetsky DS, Erlandsson-Harris H, Andersson U. (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10(3): 209. Review.
51. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. (2005) Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7(4): R817-24.
52. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, et al. (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3(3): 123-35. (Pubitemid 38961122)
53. Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, et al. (2005) Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436(7054): 1181-5. (Pubitemid 41232298)
54. Le PT, Lazorick S, Whichard LP, Haynes BF, Singer KH. (1991) Regulation of cytokine production in the human thymus: epidermal growth factor and transforming growth factor alpha regulate mRNA levels of interleukin 1 alpha (IL-1 alpha), IL-1 beta, and IL-6 in human thymic epithelial cells at a post-transcriptional level. J Exp Med 174(5): 1147-57.
55. Sims GP, Shiono H, Willcox N, Stott DI. (2001) Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 167(4): 1935-44. (Pubitemid 32747498)
56. Zuckerman NS, Howard WA, Bismuth J, Gibson K, Edelman H, et al. (2010) Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC. Eur J Immunol 40(4): 1150-61.
57. Little AJ, Corbett E, Ortega F, Schatz DG. (2013) Cooperative recruitment of HMGB1 during V(D)J recombination through interactions with RAG1 and DNA. Nucleic Acids Res 41(5): 3289-301.
58. Bergeron S, Madathiparambil T, Swanson PC. (2005) Both high mobility group (HMG)-boxes and the acidic tail of HMGB1 regulate recombination-activating gene (RAG)-mediated recombination signal synapsis and cleavage in vitro. J Biol Chem 280(35): 31314-24. (Pubitemid 41291869)
59. Calder AE, Hince MN, Dudakov JA, Chidgey AP, Boyd RL. (2011) Thymic involution: where endocrinology meets immunology. Neuroimmunomodulation 18(5): 281-9.
60. Hohlfeld R, Wekerle H. (2008) Reflections on the "intrathymic pathogenesis" of myasthenia gravis. J Neuroimmunol 201-202: 21-7
61. Papatestas AE, Alpert LI, Osserman KE, Osserman RS, Kark AE. (1971) Studies in myasthenia gravis: effects of thymectomy. Results on 185 patients with nonthymomatous and thymomatous myasthenia gravis, 1941-1969. Am J Med 50(4): 465-74.
62. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, et al. (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12(9): 875-84.
63. Savchenko AS, Hasegawa G, Naito M. (2006) Development and maturation of thymic dendritic cells during human ontogeny. Cell Tissue Res 325(3): 455-60. (Pubitemid 44126160)
64. Jablonska-Mestanova V, Sisovsky V, Danisovic L, Polak S, Varga I. (2013) The normal human newborns thymus. Bratisl Lek Listy 114(7): 402-8.
65. Raica M, Encicǎ S, Motoc A, Cîmpean AM, Scridon T et al. (2006) Structural heterogeneity and immunohistochemical profile of Hassall corpuscles in normal human thymus. Ann Anat 188(4): 345-52. (Pubitemid 43960715)
66. Raica M, Cîmpean AM, Encicǎ S, et al. (2007) Involution of the thymus: a possible diagnostic pitfall. Rom J Morphol Embryol 48(2): 101-6.
67. Raica M, Cîmpean AM, Encicǎ S, Cornea R. (2012) Immunohistological characterization of thymic dendritic cells. In Vivo 26(6): 985-92.
68. Kondo K, Mukai K, Sato Y, Matsuno Y, Shimosato Y, et al. (1990) An immunohistochemical study of thymic epithelial tumors. III. The distribution of interdigitating reticulum cells and S-100 beta-positive small lymphocytes. Am J Surg Pathol 14(12): 1139-47.
69. Gao K, Wang YC, Ma XH, Li T, Wu Z, et al. (2008) [Expression of Toll-like receptors in thymus of myasthenia gravis patients]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25(3): 311-4. [Article in Chinese[
70. Omatsu M, Kunimura T, Mikogami T, Hamatani S, Shiokawa A, et al. (2012) Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies. Gen Thorac Cardiovasc Surg 60(12): 803-10.
71. Ramasamy R, Yan SF, Schmidt AM. (2009) RAGE: therapeutic target and biomarker of the inflammatory response - the evidence mounts. J Leukoc Biol 86(3): 505-12.
72. Detterbeck F, Giaccone G, Loehrer P, Suster S, Wright C. (2010) International thymic malignancy interest group. J Thorac Oncol 5(1): 1-2
73. Ruffini E, Van Raemdonck D, Detterbeck F, Rocco G, Thomas P, et al. (2011) European Society of Thoracic Surgeons Thymic Questionnaire Working Group. Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol 6(3): 614-23